Adakveo (crizanlizumab-tmca) coverage
Customize your policy alerts
Sign up for Geisinger Health Plan Policy MBP 212.0 alerts
Get alerted when Policy MBP 212.0 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity and prior authorization criteria for Adakveo (crizanlizumab-tmca) for members of Geisinger Health Plan across applicable lines of business (Commercial, Medicare, CHIP).
LOB table, taglines, removed Medicaid business segment.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.